The role of monoamine oxidase inhibitors in depression treatment guidelines

Journal of Clinical Psychiatry

Volumn 73, Issue SUPPL. 1, 2012, Pages 10-16

  Thase, Michael E ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; PLACEBO; SELEGILINE; TRICYCLIC ANTIDEPRESSANT AGENT;

APPLICATION SITE REACTION; DEPRESSION; DIZZINESS; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; HUMAN; HYPERTENSIVE CRISIS; INSOMNIA; MAJOR DEPRESSION; MYALGIA; MYOCLONUS; NAUSEA; ORTHOSTATIC HYPOTENSION; PARESTHESIA; PARKINSON DISEASE; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SEDATION; SEROTONIN SYNDROME; SEXUAL DYSFUNCTION; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT PLANNING; WEIGHT GAIN;

EID: 84864847215     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.11096su1c.02     Document Type: Review

References (19)

1. Krishnan KR. Revisiting monoamine oxidase inhibitors. J Clin Psychiatry. 2007;68(suppl 8):35-41. PubMed
2. Wimbiscus M, Kostenko O, Malone D. MAO inhibitors: risks, benefits, and lore. Cleve Clin J Med. 2010;77(12):859-882. doi:10.3949/cjm.7a.09103 PubMed
3. Thase ME, Trivedi MH, Rush AJ. MAOIs in the contemporary treatment of depression. Neuropsychopharmacology. 1995;12(3):185-219. doi:10.1016/0893- 13X(94)058-8 PubMed
4. Lotufo-Neto F, Trivedi M, Thase ME. Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression. Neuropsychopharmacology. 1999;20(3): 226-247. doi:10.1016/S0893-13X(98)075-X PubMed
5. Fiedorowicz JG, Swartz KL. The role of monoamine oxidase inhibitors in current psychiatric practice. J Psychiatr Pract. 2004;10(4):239-248. doi:10.1097/0131746-204070-05 PubMed
6. Gardner DM, Shulman KI, Walker SE, et al. The making of a user friendly MAOI diet. J Clin Psychiatry. 1996;57(3):99-104. PubMed
7. Wecker L, James S, Copeland N, et al. Transdermal selegiline: targeted effects on monoamine oxidases in the brain. Biol Psychiatry. 2003;54(10):1099-1104. doi:10.1016/S06-323(02)01892-9 PubMed
8. Patkar AA, Pae CU, Masand PS. Transdermal selegiline: the new generation of monoamine oxidase inhibitors. CNS Spectr. 2006;11(5):363-375. PubMed
9. Stahl SM, Felker A. Monoamine oxidase inhibitors: a modern guide to an unrequited class of antidepressants. CNS Spectr. 2008;13(10):855-870. PubMed
10. Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991;148(6):705-713. PubMed
11. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition. Washington, DC: American Psychiatric Association; 2010. http://psychiatryonline.org/content. aspx?bookid=28§ionid=1667485. Accessed April 17, 2012.
12. Rapaport MH. Translating the evidence on atypical depression into clinical practice. J Clin Psychiatry. 2007;68(suppl 3):31-36. PubMed
13. Parker GB. Atypical depression: a valid subtype? J Clin Psychiatry. 2007;68(suppl 3):18-22. PubMed
14. Nutt DJ, Davidson JRT, Gelenberg AJ, et al. International consensus statement on major depressive disorder. J Clin Psychiatry. 2010;71(suppl E1):e08. PubMed
15. Anderson IM, Ferrier IN, Baldwin RC, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol. 2008;22(4):343-396. http://www.bap.org.uk/pdfs/antidepressants.pdf. Accessed April 17, 2012. doi:10.17/026981070841 PubMed
16. Lam RW, Kennedy SH, Grigoriadis S, et al, for the Canadian Network for Mood and Anxiety Treatments (CANMAT). Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults, pt 3: pharmacotherapy. J Affect Disord. 2009;117(suppl 1):S26-S43. doi:10.1016/j.jad.209.06.041 PubMed
17. National Institute for Health and Clinical Excellence. Depression: the Treatment and Management of Depression in Adults. London, United Kingdom: National Institute for Health and Clinical Excellence; 2009. http://www.nice.org.uk/nicemedia/live/12329/45888/45888.pdf. Accessed April 17, 2012.
18. Suehs BT, Argo TR, Bendele SD, et al. Texas Medication Algorithm Project Procedural Manual: Major Depressive Disorder Algorithms. Austin, TX: Texas Department of State Health Services; 2008. http://www.pbhcare.org/pubdocs/ upload/documents/TMAP%20Depression%202010.pdf. Accessed April 17, 2012.
19. Bauer M, Whybrow PC, Angst J, et al, for the World Federation of Societies Biological Psychiatry Task Force on Treatment Guidelines for Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, pt 1: acute and continuation treatment of major depressive disorder. World J Biol Psychiatry. 2002;3(1):5-43. http://www.wfsbp.org/fileadmin/pdf/guides/ 827MDDTreatmentBauer.pdf. Accessed April 17, 2012. doi:10.3109/156297020915059 PubMed